ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025
Clinical Spectrum of Epstein Barr Viremia in Hematological Disorders: Case Series and Review of Literature.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most primary Ebstein-Barr Virus (EBV) infections are asymptomatic, with up to 35% developing infectious mononucleosis (IM). After the initial primary infection (PI), EBV can undergo lytic replication and cause secondary manifestations like chronic active EBV, autoimmune diseases, or tumorigenesis. We aim to highlight the hematological spectrum of EBV and discuss its management. This is a retrospective case series of five adults (> 20 years) with confirmed EBV infection by quantitative polymerase chain reaction (QPCR) in peripheral blood. Case one showed a delayed PI with EBV in a 37-year-old female with generalized lymphadenopathy and spontaneous resolution. Case two was a complicated PI with severe nasal obstruction requiring steroids. Case three was EBV-induced Natural killer / T cell lymphoma with a complete response to modified SMILE therapy and radiation. Cases four and five demonstrate post-allogeneic hematopoietic stem cell transplant (alloHSCT) scenarios of EBV viremia and role of pre-emptive therapy. EBV infection can mimic lymphomas and should be tested in all adults with fever and lymphadenopathy. Although self-limiting, some EBV PI may need steroids. Early EBV QPCR monitoring can aid in prognostication and diagnosis. Post-alloHSCT EB viremia needs monitoring from four weeks to 12 months, especially with ongoing immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.